Vortioxetine hydrobromide;Vortioxetine Hbr NEW

Factory Provide Anti-Depressant Vortioxetine Hydrobromide CAS 960203-27-4 Vortioxetine Hbr

Introduction

Product Name : Vortioxetine hydrobromide

Other name:1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine hydrobromide;Lu AA21004 (HBr);Lu AA 21004 hydrobromide;Vortioxetine hydrobromide;LU AA21004 HBR;VORTIOXETINE HBR

CAS No.:960203-27-4

MF:C18H23BrN2S

Purity :99%

MW:379.36

Melting Point :>223°C (dec.)

Appearance: white to off white powder

Storage :Sealed in dry,Sealed in dry,Room Temperature

Vortioxetine hydrobromide is a new diarylthioalkylamine antidepressant jointly developed by Takeda (Japan) and Lingbei (Denmark) for the treatment of depression and anxiety disorders. In September 2013, it was approved for marketing by the US FDA under the trade name Brintellix for the treatment of major depressive disorder in adults, and in October of the same year, the marketing authorization application (MAA) for Vortioxetine was granted by the European Medicines In October of the same year, the marketing authorization application (MAA) for vortioxetine received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), which recommended approval of Brintellix for the treatment of adult patients with major depressive disorder (MDD), and in December 2013, the EMA European Commission granted marketing rights for vortioxetine throughout the European Union in four marketed sizes: 5 mg, 10 mg, 15 mg, and 20 mg. Vortioxetine is available in four sizes: 5mg, 10mg, 15mg and 20mg.

Function and Application 

1.Vortioxetine Hydrobromide is a multimodal serotonergic agent that inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT (1,2,3).
2. Vortioxetine hydrobromide is a new diarylthioalkylamine antidepressant jointly developed by Takeda of Japan and Lingbei of Denmark for the treatment of depression and anxiety disorders.